VAXIN LAUNCHES JOINT VENTURE WITH ANC BIO IN KOREA
Cipher announces enrollment of first patient in CIP-ISOTRETINOIN Phase III safety study
Antisoma to amend ACCEDE phase III study of AS1413
Plexxikon Treats Initial Patient With First-in-Class Drug in Phase 1 Trial
To keep up to date with news from this category use our
Ortho Clinical Diagnostics Launches First-of-its-kind Remote Monitoring Center 24 Hour Central Command Center now Offers Predictive and Proactive Diagnostic Monitoring Service in Eight Languages to Clinical Laboratories in 18 Countries Using VITROS
Paris, France (November 4th, 2009) Ortho Clinical Diagnostics (OCD) today announced the launch of a first-of-its-kind 24-7 central command center in Strasbourg, France, that continuously tracks the condition of clinical...
Inspire Completes Patient Enrollment in Three Late-Stage Clinical Trials in Cystic Fibrosis, Dry Eye and Blepharitis
DURHAM, N.C.-- November 4, 2009-- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today patient enrollment is complete in three of its late-stage clinical trials.
Transgene: First Patient enrolled in Phase I Trial of TG4023 for the Treatment of Liver Tumours
Strasbourg, France, November, 4th, 2009 - Transgene S.A. (Euronext Paris: FR0005175080) today announced the enrolment of the first patient in the Phase I trial of TG4023 (MVA-FCU1), its newest product to enter clinical...
Thirteen Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International Conference
SOUTH SAN FRANCISCO, Calif.-- November 4, 2009-- Exelixis, Inc. (Nasdaq: EXEL) announced today that thirteen abstracts related to the company's development candidates have been accepted for presentation at the 2009...
Antigenics Provides Details On GlaxoSmithKline's Pivotal Malaria Vaccine Trial With QS-21 Adjuvant
LEXINGTON, MA - November 4, 2009 - Antigenics, Inc. (NASDAQ: AGEN) today indicated that GlaxoSmithKline's (GSK) Phase III malaria vaccine clinical trial, containing Antigenics' QS-21 Stimulon
AlphaVax Progresses a Prophylactic HSV Vaccine
November 04, 2009--The development of an effective prophylactic vaccine against herpes simplex virus (HSV) is a key product opportunity for which the AlphaVax vector platform is ideally suited. [HSV Program]. Recently,...
Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer
CAMBRIDGE, Mass. November 4, 2009 Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the...
Phase Forward Teams with PharmaNet Development Group
WALTHAM, Mass.---Nov. 4, 2009-- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year agreement with PharmaNet Development Group,...
Phase Forward to Present at the 18th Annual Credit Suisse Healthcare Conference
WALTHAM, Mass.----Nov. 4, 2009-- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its senior vice president and chief financial officer,...
Nabi Biopharmaceuticals Completes Sale of PentaStaph(TM) to GlaxoSmithKline PLC
ROCKVILLE, Md., November 4, 2009 -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced that it has completed the sale of PentaStaph(TM) (Pentavalent S. aureus Vaccine) and related assets to GlaxoSmithKline PLC (GSK). The...
Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
NOVATO, Calif., Nov. 4, 2009 -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP), today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be...
New Phase IIa data on TMC435 in patients with hepatitis C presented at the ongoing AASLD - meeting
November 04, 2009 -- Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of the American Association for the Study of Liver Diseases in Boston, USA.
Cellectis bioresearch launches cGPS
Paris, November 4, 2009 - Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis S.A. (Alternext: ALCLS), today launched cGPS
Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009
CAMBRIDGE, Mass.-- November 3, 2009-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today presents preclinical data on the mechanism by which IMO-2125 was shown to induce immune activation through Toll-like Receptor 9...
Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
CAMBRIDGE, Mass., November 3, 2009 -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, announced today...
ViiV Healthcare launches: A new specialist HIV company dedicated to delivering advances in HIV treatment and care
Tuesday 3 November 2009 -- Today, ViiV Healthcare, a new specialist HIV company established by GlaxoSmithKline (GSK) and Pfizer, was officially launched. Dr Dominique Limet, the Chief Executive Officer of ViiV...
Enobia Pharma Expands Clinical Program for ENB-0040, a Bone-Targeted Enzyme Replacement Therapy for Hypophosphatasia
MONTREAL, November 3, 2009 -- Enobia Pharma announced today the initiation of a Phase 2 clinical study of ENB-0040, a bone-targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia...
Nabi Biopharmaceuticals Initiates Pivotal Phase III Study for NicVAX as an Aid to Smoking Cessation and Long-term Abstinence
ROCKVILLE, Md., November 3, 2009 -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced that it has initiated the first of two pivotal Phase III clinical trials for NicVAX(R) (Nicotine Conjugate Vaccine), the company's...
Databases locked in both the phase III clinical studies with SBG for diabetic foot ulcer
November 03, 2009--Biotec Pharmacon is pleased to inform that all data management procedures have been completed, and that the databases have been locked in both of the company's phase III studies with soluble...
BIOLASE Introduces the Diolase 10(TM) Diode Laser for Pain Management, Therapeutic Applications
IRVINE, CA, Nov 03, 2009 -- BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, today announced the launch of the Diolase 10(TM) Diode Laser for therapeutic applications, including...
MediciNova Announces Initiation of a Phase Ib Clinical Trial for MN-221 in Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease
SAN DIEGO, November 3, 2009 -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:...
GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus
Monday 2nd November 2009, London UK & Philadelphia US --GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Benlysta(TM) (belimumab) met the primary endpoint in BLISS-76, the...
BIOVEX ANNOUNCES PUBLICATION OF PHASE 2 MELANOMA RESULTS WITH ONCOVEXGM-CSF IN THE JOURNAL OF CLINICAL ONCOLOGY
Woburn, MA, November 2, 2009 -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2...
IRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM TWO PIVOTAL PHASE 3 TRIALS IN PATIENTS WITH CHRONIC CONSTIPATION
CAMBRIDGE, Mass. and New York, November 2, 2009 -- Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top line results from two Phase 3 clinical trials assessing the safety...
Pharsight Launches Phoenix NLME(TM), Continues to Build Next-Generation Platform for Model-Based Drug Development
ST. LOUIS, MO - November 2, 2009 - Pharsight, a market-leading provider of software and scientific services to improve productivity and decision-making in clinical drug development, today announced the launch of Phoenix...
PHASE ONE COMPLETE AT PENN PHARMA
November 02, 2009--Leading bioscience company, Penn Pharma has completed the first phase of its
Lundbeck starts clinical phase IIa with Lu AA24493 (cEPO) in Friedreich's ataxia in a study also assessing efficacy via biomarkers
November 02, 2009 -- H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase IIa clinical studies with the innovative project Lu AA24493 in order to evaluate safety and...
YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
MISSISSAUGA, ON, Nov. 2 , 2009 - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at...
Novavax Reports Positive Data for its Trivalent Seasonal Influenza (VLP) Vaccine Candidate in a Second Phase II Study
ROCKVILLE, MD (November 2, 2009) - Novavax, Inc. (NASDAQ: NVAX) a clinical-stage vaccine company, announced today that the Company made a poster presentation on the "Safety and Immunogenicity of a Recombinant Trivalent...
Additional Data from Fidaxomicins Phase 3 Study for Clostridium difficile infection (CDI) Presented at IDSA Annual Meeting
SAN DIEGO- October 31, 2009 - Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the presentation of new data from fidaxomicin's North American phase 3 study at the 47th Annual Meeting of the Infectious...
Cancer trials and good manufacturing practice
October 30, 2009--An article in Friday's issue of the Danish medical journal 'Dagens Medicin' accuses the Danish Medicines Agency of delaying the development of new cancer medicine. The specific case involves an...
Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
October 30, 2009 -- H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase I clinical studies with Lu 02-750 in order to investigate safety, tolerability and the...
Canadian authorities grant product approval for Intercell's Vaccine to prevent Japanese Encephalitis
Vienna, Austria, October 30, 2009 - Intercell AG (VSE: ICLL) today announced that the Health Canada granted product approval for IXIARO
Bayer HealthCare Pharmaceuticals (BAY) Presents Florbetaben Phase II Study Results at World Congress of Neurology
BANGKOK, Oct. 30 -- Bayer HealthCare presented results from a global Phase II study of florbetaben, its imaging agent in development for the detection of cerebral beta-Amyloid plaques, at the 19th World Congress of...
Echo Therapeutics Announces Significant Advance in Development of its One-Piece, Needle Free Symphony tCGM Biosensor
FRANKLIN, Mass., October 29, 2009 -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal...
MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients
MOUNTAIN VIEW, Calif., October 29, 2009 -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has completed a planned interim safety review of the open-label, long-term safety extension of the company's...
CEL-SCI Corporation Strengthens Balance Sheet Through Receipt of $10 Million From Warrant Exercises
VIENNA, Va., Oct. 26 -- CEL-SCI Corporation (NYSE Amex: CVM) announced today that it has received over $10 million over the past 60 days through the exercise of warrants by investors to purchase the Company's common...
Bayer and Onyx Initiate Phase III Trial of Nexavar
Berlin, October 23, 2009 - Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that the companies have begun enrolling patients in an international Phase III trial to evaluate Nexavar
Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer
SOUTH SAN FRANCISCO, Calif. & NEW YORK-- October 23, 2009-- Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today reported updated phase 2 clinical data which show that XL184 demonstrated...
ABLYNX WINS AWARD FOR 'MOST SUCCESSFUL EARLY PHASE TRIAL'
GHENT, Belgium, 23 October 2009 - Ablynx [Euronext Brussels: ABLX] is pleased to announce it has been awarded ,,Most Successful Early Phase Trial' at the 2009 Good Clinical Practice Journal's (GCPj) Clinical Research...
Pandemic (H1N1) 2009 Influenza Update: Experience of GSK's H1N1 adjuvanted vaccine, Pandemrix(TM), and preliminary paediatric results
October 23, 2009 -- GlaxoSmithKline (GSK) today announced that, to date, more than 150,000 people have received GSK's pandemic H1N1 vaccine, Pandemrix(TM), as part of Government initiated vaccination programmes across...
Strategic Collaboration with Kineta
MATTAWAN, MI October 23, 2009: MPI Research announced that it will be collaborating with Kineta, Inc, a Seattle-based biotechnology company, in advancing their promising autoimmune drug development program. This...
Movetis obtains EU authorisation for the commercialisation of Resolor
Turnhout, October 22, 2009 Movetis, the GI specialty pharmaceutical company based in Belgium, announces that it has obtained approval from the European Commission for the commercialisation of its lead product Resolor...
Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma
SEATTLE, Oct. 22 -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an...
Ophthalmic Imaging Systems to Launch OIS EyeScan and Other New Products at the American Academy of Ophthalmology's (AAO) 113th Annual Meeting
SACRAMENTO, CA--(10/22/09) - Ophthalmic Imaging Systems ("OIS" or "the Company") (OTC.BB:OISI - News), a leading digital imaging and informatics company, today announced that it will launch two new products and...
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial with Subcutaneous Herceptin(R)
SAN DIEGO, Oct 22, 2009 -- Halozyme Therapeutics, Inc. (Nasdaq:HALO) and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze(TM) technology (rHuPH20, recombinant human...
SciClone Announces Enrollment of First Patient in Its Phase 2 Trial of SCV-07 in Hepatitis C
FOSTER CITY, CA, Oct 21, 2009 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of its first patient at the Atlanta Gastroenterology Associates in Atlanta, GA, in a phase 2 trial of SCV-07...
Crucell HIV Vaccine: Promising Preliminary Results Phase I Study Presented by Dr Dan Barouch at AIDS Vaccine 2009 in Paris
Leiden, The Netherlands (October 21, 2009) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that preliminary results of the Phase I study of its HIV vaccine were...
Two new appointments to BioAlliance Pharma's Supervisory Board in phase with the company's development
Paris, October 21, 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the appointment of two new Board members.
Argos Therapeutics Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis(TM) HIV Program at the AIDS Vaccine 2009 Conference
Durham, NC and Paris, France- October 21, 2009 -- Argos Therapeutics today announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response and safety data from an ongoing...
Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement for novel oral agent to treat Type II Diabetes
Paris, France - October 21, 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Wellstat Therapeutics Corporation announced today a global licensing agreement on PN2034, a novel oral first-in-class, insulin...
Novavax and Xcellerex Announce Collaboration to Develop Large-scale Manufacturing Process for 2009 H1N1 Influenza VLP Vaccine
Rockville, MD and Marlborough, MA - October 21, 2009 - Novavax, Inc. (NASDAQ: NVAX) and Xcellerex, Inc. has entered into a strategic collaboration to accelerate the development of Novavax's vaccine manufacturing process...
Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data at the IDF's 20TH World Diabetes Congress
MONTREAL, CANADA - October 21, 2009 - Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity,...
PharmaNet Development Group Management Participates In The 8th Annual Partnerships In Clinical Trials Conference In Rotterdam
Princeton, NJ - October 21, 2009 - PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, today announced its...
Alfacell Corporation Announces Closing of $3.25 Million Private Placement
SOMERSET, N.J., Oct. 20, 2009 -- Alfacell Corporation (Pink Sheets:ACEL) today announced that it has closed a private placement with certain investors in which it raised $3.25 million in gross proceeds through the sale...
Gore Announces First Implant of Next Generation Conformable GORE TAG
October 20, 2009--W. L. Gore & Associates (Gore) today announced the first human implants of the next generation Conformable GORE TAG
Sernova's Cell Pouch System(tm) and Sertolin(tm) Preclinical Efficacy Presented at Leading International Islet Transplant Conference
LONDON, ONTARIO--(Oct. 20, 2009) - Sernova Corp. (TSX VENTURE:SVA - News) is pleased to provide a summary of results of islet transplantation studies related to its Cell Pouch System(TM) and Sertolin(TM) technologies...
Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma
SEATTLE, Oct. 22-- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an...
Interim analysis of an ongoing phase II study with nicotine vaccine shows primary endpoint not achieved
Schlieren (Zurich), Switzerland, October 15, 2009 - Cytos Biotechnology Ltd (SIX:CYTN) was informed today by Novartis that an interim analysis of a Phase II study with the nicotine vaccine NIC002 showed that the primary...
Affymetrix Launches New Platform for Next-Generation Genotyping
SANTA CLARA, Calif.--Oct. 14, 2009-- Affymetrix, Inc. (Nasdaq:AFFX) today announced the launch of the Axiom Genotyping Solution, its next-generation array technology designed to match the significant rise in genetic...
New Preclinical Data confirms PG545 as a promising clinical candidate for cancer
Brisbane, Australia, 14 October 2009: Progen Pharmaceuticals Limited (ASX:PGL; NASDAQ: PGLA) today announced that new preclinical data on PG545, a dual antiangiogenic and anti-heparanase inhibitor, will be presented at...
Phase Forward and Merck Team Up to Win Society for Clinical Data Management Data Driven Innovation Award
WALTHAM, Mass.---Oct. 14, 2009-- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that a joint project with customer Merck & Co. has won...
VAXIN LAUNCHES JOINT VENTURE WITH ANC BIO IN KOREA
Birmingham, Alabama - October 14, 2009 - Vaxin Inc., an emerging vaccine company today announced that it has entered into a joint venture with South Korean biomedical company, AnC Bio Group to develop, manufacture and...
Intercell starts European Pivotal Phase III clinical trial for the patch-based Travelers' Diarrhea Vaccine
Vienna (Austria) and Gaithersburg (USA), October 14, 2009 - Intercell AG (VSE: ICLL) announced today that its Travelers' Diarrhea (TD) Vaccine Patch has entered clinical Phase III development. A pivotal efficacy field...
IMS Launches MIDAS Global Biologics, Delivering New Market Insights for Enhanced Portfolio Planning
NORWALK, CT, October 14, 2009 - IMS Health (NYSE: RX), the world's leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the launch of IMS MIDAS Global Biologics(TM), a...
Hanmi's LAPS-GCSF got the US FDA's approval for clinical trials
October 14, 2009 - Hanmi Pharmaceutical Co., Ltd. announced on October 14 that the U.S. Food and Drug Administration(FDA) had approved the first phase of clinical trials of 'LAPS-GCSF (HM10460A)' which Hanmi...
Jessica Biel, Alexandra Cousteau, Pete Wentz, Angelique Kidjo, and Jenny Fletcher Join Live Earth, Global Water Challenge and Dow to Launch the Dow Live Earth Run For Water - the Largest Global Water Initiative in History to Help Solve the World Water Crisis
New York - October 13, 2009 --Today, Live Earth announced plans to implement the largest worldwide water initiative on record to help combat the global water crisis. The Dow Live Earth Run for Water - to take place...
Almac and Edinburgh Instruments launch FLEXYTE fluorescence lifetime assays at MipTec
October 13, 2009--Almac, a leading provider of integrated research, development and manufacturing services to the pharmaceutical industry and Edinburgh Instruments, manufacturers of fluorescence spectrometers, have...
Allos Therapeutics Announces Closing of Public Offering
WESTMINSTER, Colo.--Oct. 13, 2009-- Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the closing of its previously announced underwritten public offering of 14,000,000 shares of newly issued common stock at a...
TcLand Expression Launches An International, Multicenter Clinical Validation Study
Nantes, France, October 13, 2009 - TcLand Expression SA, a global leader in the field of gene expression biomarkers in immunology, today announced the launch of the KARE study (Kidney Allograft REjection). This will be...
Fresenius Medical Care introduces programme for improved PD therapy
October 13, 2009 - Fresenius Medical Care, the world's largest provider of dialysis products and services, has launched a new therapy programme for peritoneal dialysis (PD). 'P3', the first comprehensive PD care concept...
Depomed Reports Results From Two Phase 3 Clinical Trials Evaluating Non-Hormonal Therapy for Menopausal Hot Flashes
MENLO PARK, Calif., Oct 12, 2009 -- Depomed, Inc. (NASDAQ:DEPO) announced today top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an investigational...
BioAlliance Pharma announces Phase I trial for Fentanyl Lauriad
Paris, October 12, 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the approval from the French Drug Agency...
GE HEALTHCARE CONTINUES ADVANCEMENT OF NUCLEAR MEDICINE WITH LAUNCH OF DISCOVERY NM/CT 670
Barcelona, Spain October 11, 2009 - GE Healthcare, a unit of General Electric Company (NYSE:GE), announced the European launch of Discovery NM/CT 670, a hybrid imaging platform designed to improve workflow, dose...
Aperio's SecondSlide(TM) Digital Slide Sharing Service Included in College of American Pathologists Diagnostic Work Station Prototype
Vista, CA - October 9, 2009 - Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry is pleased to announce that SecondSlide(TM), its newly launched...
Bio3 Research Inc. (Hayward/CA/USA), a fully owned subsidiary of Bio3 Research s.r.l.
October 9, 2009--Bio3 Research Inc. (Hayward/CA/USA), a fully owned subsidiary of Bio3 Research s.r.l. (Milano/Italy) is pleased to announce the beginning of the in house production (GLP) of HMGB1 protein from E.Coli...
MediGene successfully completes patient recruitment into EndoTAG(TM)-1 Phase II breast cancer trial
Martinsried/Munich, October 9, 2009. MediGene AG (Frankfurt: MDG, Prime Standard, TecDAX) has successfully completed patient recruitment into its randomized Phase II trial of EndoTAG(TM)-1 for the treatment of triple...
MDS Announces Agreement to Sell Central Labs Operation to Czura Thornton
TORONTO, October 9, 2009 - MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, today announced that it has signed an agreement to sell its Central Labs...
Lpath's iSONEP Is Well Tolerated at All Dose Levels in a Phase 1 Trial in Wet-AMD Patients
SAN DIEGO, CA, October 08, 2009 -- Lpath, Inc. (OTCBB: LPTN), the category leader in lipidomics-based therapeutics, reported positive summary results of its single-dose Phase 1 clinical trial of iSONEP(TM) in wet-AMD...
Antisoma to amend ACCEDE phase III study of AS1413
London, UK, and Cambridge, MA: 08 October 2009 Antisoma announces that, following discussions with FDA and trial investigators, it plans to amend the primary endpoint in the ACCEDE study of AS1413. The ACCEDE study is...
ABAXIS Announces Launch of the First Fully Automated Canine Wellness Profile That Includes a Canine Heartworm Antigen Test
UNION CITY, Calif., Oct. 8 -- Abaxis, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis instruments for the medical, research and veterinary markets, announced today that it has...
Plexxikon Treats Initial Patient With First-in-Class Drug in Phase 1 Trial
BERKELEY, Calif. - October 8, 2009 -- Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating...
Phase Forward Announces Third Quarter Financial Reporting Date for October 29, 2009
WALTHAM, Mass.---Oct. 8, 2009-- Phase Forward Incorporated (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, announced today that it will release financial results for...
Bayer Schering Pharma collaborates with AC Immune in the field of Alzheimer
Berlin, Germany, October 8, 2009 - Bayer Schering Pharma AG, Germany, will provide its development candidate florbetaben, a so called PET (positron emission tomography) tracer, to the Swiss-based biopharmaceutical...
HEAD AND NECK TRIAL UPDATE
October 08, 2009--Viralytics Limited (ASX: VLA, OTC: VRACY) is pleased to announce that a second hospital has commenced recruitment of patients for the Company's Phase I CAVATAK(TM) trial for the treatment of Head and...
Novartis gains exclusive worldwide rights to PTK 0796, in Phase III study as potential first-in-class IV and oral broad-spectrum antibiotic
Basel, October 8, 2009 - Novartis has gained exclusive worldwide rights to market PTK 0796, potentially the first once-daily broad-spectrum antibiotic that can be given by intravenous (IV) infusion or oral tablet to...
In JCO, Danusertib results of a Phase 1 trial. Phase 2 in patients with lung cancer and other solid tumors ongoing.
Nerviano Italy, 8 October 2009 - Nerviano Medical Sciences today announced a publication in the peer-reviewed scientific journal, Journal of Clinical Oncology (*), of the first clinical trial performed in man in...
RXi Pharmaceuticals Presented New Pre-Clinical Animal Data at its Annual Investor Day
WORCESTER, Mass.----Oct. 8, 2009-- RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi),...
Panenza
Lyon, France - October 8, 2009 - Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that a single dose of influenza A (H1N1) 2009 monovalent vaccines, Panenza
NextPharma Technologies Expands its Capabilities through the Addition of Clinical Trial Services in the United States
Surrey, UK, 8th October 2009 Surrey, UK, 8th October 2009 - NextPharma, a leading service provider of product development, contract manufacturing, cold chain storage and logistics to the pharmaceutical and biotechnology...
NeuroSearch initiates a clinical study with ACR325 for the treatment of dyskinesias (involuntary movements) in Parkinson's disease
Copenhagen, 8 October 2009 - NeuroSearch (NEUR) today announced the initiation of a clinical Phase Ib study of ACR325, a dopaminergic stabiliser for the treatment of dyskinesias in Parkinson's disease. Dyskinesias are...
Bayer Schering Pharma collaborates with AC Immune in the field of Alzheimer
Berlin, Germany, October 8, 2009 - Bayer Schering Pharma AG, Germany, will provide its development candidate florbetaben, a so called PET (positron emission tomography) tracer, to the Swiss-based biopharmaceutical...
Canadian patent strengthens IP for Allon's 2nd technology platform
VANCOUVER -- October 8, 2009 - Allon Therapeutics Inc. (TSX: NPC), announced today that the intellectual property underlying its activity-dependent neurotrophic factor (ADNF) technology platform has been strengthened by...
Living Cell Technologies Invited To Speak On New Zealand DIABECELL
8 October 2009: Sydney, Australia, Auckland, New Zealand - Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) is to present at the forthcoming meeting of the International Pancreas And Islet Transplantation...
Phase 2 Study of KRX-0401 (Perifosine) in Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Open for Enrollment at Duke Comprehensive Cancer Center
NEW YORK, October 8, 2009 -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of a Phase 2 clinical study to evaluate KRX-0401 (perifosine) as a single agent treatment for relapsed or...
Canadian patent strengthens IP for Allon's 2nd technology platform
VANCOUVER -- October 8, 2009 - Allon Therapeutics Inc. (TSX: NPC), announced today that the intellectual property underlying its activity-dependent neurotrophic factor (ADNF) technology platform has been strengthened by...
Celtic Therapeutics to invest up to $15m in the development of Spirogen's cancer drug SG2000
London, United Kingdom, 08 October, 2009 - Spirogen Limited (Spirogen), the UK-based developer of DNA-interactive drugs, today announced that the private equity firm Celtic Therapeutics Holdings LP will invest up to $15...
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
